알테오젠

196170KOSDAQ

64.6 / 100

Reference Date: 2026-09-08

Financial Score28.5 / 40

News Sentiment18.1 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 6.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Alteogen is a biotech company leveraging platform technologies like Hybrozyme™, NexP™, and NexMab™ to develop and commercialize biopharmaceuticals, with licensing agreements with global pharma firms such as MSD and AstraZeneca, ensuring sustainable revenue through upfront fees, milestones, and royalties. Its key product ALT-B4 offers subcutaneous injection advantages over IV formulations, while its biosimilar business collaborates with Qilu Pharmaceutical to expand market reach.

Number of Employees

161people

Average Salary

149.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

107.80Industry Average 15.000.0Point

7.2x industry avg (risky)

PBR

—Industry Average 1.203.5Point

ROE

39.85Industry Average 8.007.0Point

5.0x industry avg (excellent)

Debt Ratio

1.02Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲58.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲340.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 22.1% (improving, 3yr)

Detailed News Sentiment

42 totalPositive 25Neutral 11Negative 6Average Sentiment Score 72.5

Positive
박기범 알테오젠 이사, '기반기술 우수연구자' 수상
알테오젠 이사의 기술개발 우수성 인정으로 기업의 연구 역량 강화 기대
Positive
[마감시황]코스닥, 822.19로 1.07% 상승 마감…반도체 장비주 ...
코스닥 상승으로 알테오젠 포함 반도체 장비주 전반에 긍정적 영향 기대
Positive
21년 만에 300곳…코스닥 '기술특례'로 8조원 끌어모았다
알테오젠의 시가총액이 카이랩스의 코스닥 기술특례 상장으로 인해 첨단산업 분야에서의 성장이 가속화되어 크게 상승했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 286,000Won52-week high 559,00052-week low 268,000

1-month return2.0Point

1m -6.23% (slight drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결)2026-09-02
Neutral투자판단관련주요경영사항 (ALT-B4 라이선스 계약 파트너사 MSD로부터 판매 마일스톤 수령 예정)2026-08-31
Neutral신규시설투자등2026-08-21
Neutral반기보고서 (2026.06)2026-08-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-13